DALLAS, December 16, 2014 /PRNewswire/ --
According to the new market research report The "Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019", published by MarketsandMarkets, the Plasma Fractionation Market was valued at $16,573.4 Million in 2014 and expected to reach nearly $25,383.4 Million by 2019, growing at a CAGR of 8.9% from 2014 to 2019.
Browse 126 Market Data Tables and 38Figures spread through 200 Pages and in-depth TOC on"Plasma Fractionation Market - Global Forecast to 2019"
Early buyers will receive 10% customization on this report.
This report studies the Plasma Fractionation Market over the forecast period of 2014-2019.
The Plasma Fractionation Market saw healthy growth during the last decade, primarily attributed to the rising aging population, increasing number of hemophilic patients, rising off-label use of albumin and immunoglobulins in various chronic diseases, increased diagnosis rate, and the increasing use of prophylactic treatment for bleeding diorders and disease of immune systems. However, the high cost and serious adverse effects of plasma products, and the emergence of recombinant products used as alternatives to plasma-derived products are hampering the growth of this market to a certain extent.
In this report, the Plasma Fractionation Market is segmented by products, applications, end users, and region. Based on type of product, the Plasma Fractionation Market is mainly segmented into albumin, immunoglobulins, coagulation factor concentrates, and others. The immunoglobulin segment is further subsegmented into intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and others. The coagulation factor concentrates segment is divided into factor VIII, factor IX, factor XIII, prothrombin coagulation concentrates, Von Willebrand factor, and fibrinogen concentrates. The various application areas of plasma fractionation products analyzed in the report include neurology, hematology, immunology, and critical care. Likewise, the major end users of this market are hospitals and clinics, clinical research laboratories, and academic institutes.
IVIg accounts for the major share of the Plasma Fractionation Market. The increasing use of IVIg in clinical areas such as neurology, hematology, immunology, rheumatology, and dermatology, and its excellent efficacy records are the key factors responsible for the growth of this market segment. In addition, the use of IVIg in a wide range of conditions, such as adult respiratory distress syndrome, fibrosis, connective tissue disease, encephalitis, heart failure, and Alzheimer's disease, is being evaluated. Positive results in such conditions would increase the demand for IVIg globally in the near future.
In 2013, North America was the leading market for plasma fractionation, followed by Europe, and Asia-Pacific. The highly developed healthcare infrastructure, advent of new technologies, growing aging population, and favorable regulatory framework in the North American and European regions has led to the large market shares of these regions. However, the highest growth opportunities for this market are in the Asia-Pacific region.
The major players in the global Plasma Fractionation Market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.), Sanquin (Netherland), Laboratoire Français du Fractionnement et des Biotechnologies (France), and Biotest (Germany).
Browse Related Reports:
Protein Expression Market by Products (Expression Vector, Service, Reagent), Application (Industrial, Therapeutic), Expression Systems (Mammalian, Prokaryotic, Baculovirus, Yeast) & by End User (Pharmaceutical, Biotechnology, CRO) - Global Forecast to 2018
Protein Characterization and Identification Market by Instruments (Chromatography, Electrophoresis, Mass Spectroscopy), Consumables & Services, Application (Clinical Diagnosis, Drug Discovery & Development), & by End Users - Global Forecast to 2019
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology